Objective-Very low-density lipoprotein assembly and secretion are regulated by the availability of triacylglycerol.
H epatic steatosis, the clinical manifestation of ectopic accumulation of triacylglycerol in the liver, is associated with cardiovascular diseases through increased production of proatherogenic very low-density lipoprotein (VLDL), insulin resistance, and diabetes mellitus. 1, 2 The assembly of secretion competent VLDL is dependent on the provision of lipids, triacylglycerol in particular. Acyl-CoA:diacylglycerol acyltransferase (DGAT) 1 and DGAT2 catalyze the final and only committed step in mammalian triacylglycerol biosynthesis. 3 Although both DGATs esterify diacylglycerol to triacylglycerol, the enzymes share no homology in primary amino acid sequences and are encoded by genes belonging to distinct gene families. The 2 DGATs seem to perform nonredundant physiological functions, reflected by different phenotypes of Dgat1 −/− and Dgat2 −/− mice. [3] [4] [5] Dgat2 −/− mice die within a few hours after birth because of a drastic reduction of triacylglycerol content and a severely impaired epidermal barrier protection. 5 Diminished Dgat2 expression in adult mice by antisense oligonucleotide markedly decreases hepatic triacylglycerol content and improves steatosis in obese mice. 6, 7 In contrast, Dgat1 −/− mice are viable, possibly because of a more moderate reduction in tissue triacylglycerol and a mild decrease in dietary triacylglycerol absorption. 8, 9 Moreover, plasma triacylglycerol concentration in DGAT1-deficient mice remains unchanged after a 4-hour fasting, suggesting a relatively minor role of DGAT1 in hepatic lipoprotein production. 3, 10 Although extensive investigation of DGATs has been undertaken in tissues such as adipose, small intestine, and skin, less is known about their roles in hepatic triacylglycerol synthesis and secretion.
Differences in fatty acid (FA) compositions of hepatic intracellular triacylglycerol and plasma VLDL triacylglycerol revealed an indirect transfer of triacylglycerol for VLDL maturation. 11 It has been established that the majority (60%-80%) of triacylglycerol in VLDL is derived from re-esterification of lipolytic products in hepatocytes. [12] [13] [14] This sinuous supply of triacylglycerol for VLDL maturation overcomes the inability of triacylglycerol stored in cytosolic lipid droplets (LDs) to cross the lipid bilayer of the endoplasmic reticulum (ER) and provides a mechanism for the regulation of VLDL secretion independently of plasma FA and intracellular triacylglycerol concentration. 15 We have previously shown that lipases involved in the hydrolysis of preformed triacylglycerol include ER-localized carboxylesterase 1d/triacylglycerol hydrolase and arylacetamide deacetylase [16] [17] [18] ; however, it has not been determined which DGAT catalyzes the re-esterification of diacylglycerol to support VLDL maturation.
Topological studies separated DGAT activities in hepatic microsomes into overt, cytosolic side-localized, and latent, lumenal side-localized. [19] [20] [21] This led to a hypothesis that the overt DGAT activity might be responsible for the synthesis of triacylglycerol stored in cytosolic LDs, whereas the latent DGAT activity would mainly contribute to the formation of lumenal LDs, lipidation of primordial apolipoprotein B (ApoB) particles, and maturation/expansion of VLDL. 3, 22, 23 DGAT1 contains multiple transmembrane domains 24 and has been suggested to assume a dual topology within the ER of HepG2 cells, exhibiting comparable activities on both cytosolic and luminal sides of the ER membrane. 25 In contrast, DGAT2 was postulated to be intercalated into the ER bilayer through 1 or 2 transmembrane domains, with both the N and C termini oriented toward the cytosol. 20 In addition to its ER localization, DGAT2 was found on the surface of LDs in the Caenorhabditis elegans intestinal segments and Drosophila melanogaster Schneider 2 cells. 19, 26, 27 Thus, DGAT2 would be predicted to contribute to the overt activity. However, divergent DGAT1 and DGAT2 topologies might not be sufficient to assign specific roles these enzymes might play in channeling triacylglycerol for distinct metabolic functions because there seems to be a functional crosstalk between triacylglycerol residing in cytosolic LDs and ER lumenal LDs. 12, 28 To investigate distinct contributions of the 2 DGATs to hepatic triacylglycerol synthesis, deposition in LDs, and triacylglycerol secretion in VLDL, we pharmacologically inhibited their activities in primary mouse and human hepatocytes with potent, highly selective small-molecule inhibitors. 29, 30 Moreover, because some studies showed that DGAT2 preferentially used endogenously synthesized FA to form triacylglycerol in HepG2 hepatoma cell line, whereas DGAT1 was primarily responsible for exogenous FA esterification, 25, 31 we tracked lipids synthesized from FA made de novo or from exogenously supplied oleic acid.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

DGAT1 and DGAT2 Can Compensate for Each Other to Synthesize Triacylglycerol
To investigate individual DGAT function in triacylglycerol synthesis in primary mouse hepatocytes, we inhibited DGAT1 or DGAT2 activity individually or together by small-molecule inhibitors; then, we assessed de novo synthesis of triacylglycerol by incubations with [ Figure I in the online-only Data Supplement), indicating that excess exogenous oleate contributed to a significant enhancement of hepatic triacylglycerol pool, whereas FA synthesized de novo from acetate did not significantly increase intracellular triacylglycerol content. Triacylglycerol synthesis from de novo synthesized FAs (acetate precursor) was not affected by the inhibition of either DGAT1 or DGAT2 alone, and it was slightly decreased in DGAT2-inactivated cells incubated with oleate, whereas inactivation of both DGAT1 and DGAT2 dramatically reduced triacylglycerol synthesis (>80%) irrespective of whether FA was endogenously synthesized or supplied exogenously ( Figures 1A and 2A ). Moreover, DGAT inhibitors did not affect mRNA expression of either Dgat1 or Dgat2 ( Figure II in the online-only Data Supplement). Therefore, DGAT1 and DGAT2 can compensate for each other to synthesize triacylglycerol in mouse hepatocytes, although DGAT2 seems to be more efficient in esterifying exogenous FA.
Inhibition of DGATs Influences sn-1,2-Diacylglycerol and Glycerophospholipid Synthesis
Sn-1,2-diacylglycerol is at the pivotal junction of the Kennedy pathway of glycerolipid synthesis and can be converted to either phosphatidylcholine, phosphatidylethanolamine, or triacylglycerol. Destinations of sn-1,2-diacylglycerol for membrane-forming phosphatidylcholine and phosphatidylethanolamine or for energy storage as triacylglycerol are controlled by enzymes, cytidine 5′-diphosphocholine-choline/ ethanolamine:sn-1,2-diacylglycerol phosphocholine/phosphoethanolamine transferases, and DGATs, respectively. 32, 33 We postulated that inhibition of DGAT1 or DGAT2 would reduce esterification of sn-1,2-diacylglycerol to triacylglycerol and increase channeling of sn-1,2-diacylglycerol to glycerophospholipid synthesis. Indeed, combined inhibition of DGAT1 and DGAT2 resulted in accumulation of sn-1,2-diacylglycerol, which also occurred to a lesser but significant degree on inhibition of DGAT2 but not DGAT1 alone ( Figures 1B and 2B) . These results suggest a more active role of DGAT2 in hepatic triacylglycerol synthesis, in agreement with previous reports showing that reduction of Dgat2, but not Dgat1, expression by antisense oligonucleotide decreased hepatic triacylglycerol levels in high-fat diet-induced obese mice. 6, 7 Nonstandard Abbreviations and Acronyms Although increased sn-1,2-diacylglycerol availability from de novo lipogenesis (acetate) did not lead to enhanced phosphatidylcholine or phosphatidylethanolamine synthesis ( Figure 1C and 1D), sn-1,2-diacylglycerol produced from exogenous oleic acid was channeled to glycerophospholipid synthesis ( Figure 2C 
DGAT2 Promotes Whereas DGAT1 Restricts Cytosolic LD Growth in Mouse Hepatocytes
Phosphatidylcholine acts as a surfactant to prevent LD coalescence, and genetic ablation of CTP:phosphocholine cytidylyltransferase α, the rate-limiting enzyme in phosphatidylcholine synthesis, results in giant LDs. [34] [35] [36] We therefore hypothesized that the observed increased phosphatidylcholine synthesis from exogenous oleate ( Figure 2C ) would alter LD morphology. To test this hypothesis, LD biogenesis was stimulated by incubation of hepatocytes with oleate together with a trace of Bodipy FA analogue. The experimental protocol was laid out as presented in the schematic diagram ( Figure 3A , (1)), and representative images from this experiment are shown in Figure 3B (top). Thirty cells were analyzed in each group. The number of LDs per cell did not change unless both of the DGATs were inactivated. The mean area of individual LD and the percentage of large LDs (area, >3 μm 2 ) were decreased, and the frequency of small LDs (area, <1 μm 2 ) was increased when DGAT2 or both DGATs were inhibited, whereas DGAT1 inhibition exerted opposite effects ( Figure 3C ).
Next, we investigated whether any morphological changes would occur in LDs containing preformed triacylglycerol, in other words, when DGAT activity was inhibited during triacylglycerol turnover. The experimental protocol is shown in the schematic diagram ( Figure 3A, (2)), and representative images from this experiment are shown in Figure 3B (bottom). Thirty cells from each condition were analyzed. When DGAT2 or both DGATs were inhibited, the frequency of small LDs (area, <1 μm 2 ) was increased, accompanied with a slight increase of the number of LDs per cell, whereas the mean area and the percentage of large LDs (area, >5 μm 2 ) were decreased. DGAT1 inhibition alone had no significant influence on the size and number of preformed LDs ( Figure 3D ). The mean area of individual LD containing preformed triacylglycerol as opposed to newly synthesized triacylglycerol was larger, although the intracellular triacylglycerol content did not change (data not shown), suggesting that LD coalescence occurred during triacylglycerol turnover.
Inhibition of DGAT2, but Not DGAT1, Reduces Lipogenic Gene Expression
Because Dgat2 −/− mice exhibited markedly diminished FA levels in the liver and plasma, 5 we examined the potential modulatory role of DGATs on de novo synthesis of FA by analyzing lipogenic gene expression and SREBP1c maturation. Messenger RNA expression of genes involved in de novo lipogenesis (Acaca, Fasn, and Srebf1c) and desaturation (Scd1) was significantly downregulated on DGAT2 inhibition ( Figure 4A ). Nuclear localization of the master lipogenic transcriptional activator SREBP1c was diminished on DGAT2 inactivation ( Figure 4B ). Because of the short-time treatment with DGAT inhibitors (4 hours), changes in protein expression and metabolism may not be evident, and therefore, it was not surprising that the total amount of full-length SREBP1 precursor did not alter and nor was de novo triacylglycerol synthesis on singular DGAT2 inactivation ( Figure 1A) . Nonetheless, metabolic changes might occur during prolonged treatment with DGAT inhibitors. 
Triacylglycerol Pool Generated by DGAT1 Is Preferentially Used for Supplying Substrates for Oxidation, Whereas DGAT2-Derived triacylglycerol Is More Favored for Secretion
Although DGAT1 and DGAT2 can compensate for each other to synthesize triacylglycerol, their distinct membrane topologies, interacting protein partners, and subcellular localizations might imply different destinations and uses of their products. 3 Neutral lipids stored in the cytosol or ER lumen of hepatocytes are destined for distinct uses. ER lumenal triacylglycerol is deposited into primordial ApoB particles or resident ER lumenal LDs, both closely correlated with VLDL maturation, 13, 37 whereas triacylglycerol stored in cytosolic LDs provides FA for oxidation in mitochondria. 38, 39 Thus, we first examined whether DGAT1 or DGAT2 inactivation would affect intracellular triacylglycerol distribution by analyzing the proportion of newly synthesized triacylglycerol dispensed into cytosol and membranes. However, no change in the subcellular localization of synthesized triacylglycerol was observed when either DGAT was inhibited ( Figure V in the online-only Data Supplement). This is perhaps not surprising because the capacity of triacylglycerol storage within the ER bilayer is limited, and triacylglycerol stored in cytosolic and ER lumenal depots is intimately linked. 37, [40] [41] [42] [43] We next addressed whether inactivation of DGATs directly influences triacylglycerol use using an experimental protocol shown in Figure 5A . After the chase period, radioactivity in acid soluble metabolites and medium triacylglycerol was measured, which indicated FA oxidation and VLDL secretion, respectively. Inhibition of DGAT2 (triacylglycerol synthesized by DGAT1) augmented FA oxidation, whereas DGAT1 inhibition (triacylglycerol synthesized by DGAT2) had no effect on FA oxidation ( Figure 5B ), suggesting that DGAT1-derived triacylglycerol pool was preferentially used for FA oxidation. This observation is in agreement with previous studies in rats with diet-induced nonalcoholic fatty liver disease, where increased FA oxidation was also observed on antisense oligonucleotide-mediated decrease of Dgat2 expression. 6 Notably, reduced de novo lipogenic gene expression ( Figure 4A ) and augmented FA oxidation ( Figure 5B ) in DGAT2-inactivated hepatocytes were not accompanied by significant changes in malonyl-CoA mass during the 4-hour incubation (results not shown). On the contrary, inhibition of DGAT1 (triacylglycerol synthesized by DGAT2) increased triacylglycerol secretion, on which DGAT2 inhibition had no effect ( Figure 5C ), thus suggesting that DGAT2-derived triacylglycerol pool was more efficiently channeled to VLDL assembly. In separate experiments, to validate that DGAT inhibitors were completely removed before the chase period, cells were incubated with [ 3 H]acetic acid or [ 3 H]oleic acid during the chase period. Triacylglycerol synthesis was nearly completely recovered, suggesting that DGAT inhibitors were washed out ( Figure IV in the online-only Data Supplement).
Inhibition of DGAT2, but Not DGAT1, Reduces Re-Esterification of Lipolytic Products and Triacylglycerol Secretion Without an Effect on Extracellular ApoB Levels in Mouse Hepatocytes
To distinguish potentially different functions of DGAT1 and DGAT2 in provision of triacylglycerol for VLDL assembly by re-esterification of lipolytic products from preformed lipids, we introduced the DGAT inhibitors immediately before the chase period, that is, after lipids were synthesized from radiolabeled precursors as depicted in Figure 6A . Inhibition of DGAT2 dramatically reduced triacylglycerol secretion, suggesting a prominent role of DGAT2 in the re-esterification of diacylglycerol to form VLDL-destined triacylglycerol, although DGAT1 might have a minor additive effect because inhibition of both DGATs further dampened triacylglycerol secretion ( Figure 6B and 6C) . DGAT2 inhibition-mediated attenuation of VLDL triacylglycerol secretion was independent of microsomal triglyceride transfer protein expression ( Figure VIA and VIB in the onlineonly Data Supplement). In addition, there was no preference for FA origin used for the resynthesis of VLDL triacylglycerol because similar attenuation of VLDL secretion was observed when preformed triacylglycerol was made de novo from acetate or from exogenously supplied oleate ( Figure 6B and 6C ).
More triacylglycerol undergoes lipolysis than is required to support VLDL assembly, and excess re-esterified triacylglycerol re-enters the intracellular triacylglycerol storage pool. 15 However, it is technically challenging to segregate recycled triacylglycerol from the pre-existing triacylglycerol. To distinguish the pre-existing triacylglycerol pool from the newly synthesized triacylglycerol pool, a doublelabeling experiment was carried out, in which the preformed triacylglycerol was labeled with [ 14 C]oleic acid during an overnight incubation (pulse), followed by a 4-hour chase period, during which the newly synthesized triacylglycerol pool was labeled with [ 3 H]oleic acid. DGAT inhibitors were only present in the chase period, during which pre-existing Finally, we analyzed the effect of DGAT1 and DGAT2 inactivation on ApoB secretion. The extracellular ApoB48 and ApoB100 levels were significantly decreased after simultaneous inhibition of both DGATs but not when either of the 2 DGATs was inhibited alone ( Figure 6D ), and the lack of effect on ApoB secretion was persistent even when neither acetate nor oleate was supplemented ( Figure VIC in the online-only Data Supplement). This suggested that DGAT2 inactivation leads to secretion of less lipidated thus denser ApoB. To test this inference, we determined the lipoprotein densities after DGAT inhibition by density gradient centrifugation of secreted [ 35 S]-labeled ApoB. ApoB100 and ApoB48 shifted to fractions of higher densities when DGAT2 or both of the DGATs were inhibited ( Figure 6E ). However, this was more obvious in cells supplemented with oleate than acetate, possibly because incubation with acetate did not stimulate substantial triacylglycerol synthesis and therefore VLDL secretion.
In conclusion, in mouse hepatocytes, DGAT2 plays the dominant role in the re-esterification process and acts as a driving force in facilitation of VLDL maturation, without altering extracellular ApoB levels.
DGAT1 and DGAT2 Regulate VLDL Secretion in a Similar Pattern in Humans as in Mouse Hepatocytes
Although mouse hepatocytes secrete ApoB48 and ApoB100 lipoproteins, human hepatocytes secrete lipoproteins only containing ApoB100, because the latter do not express APOBEC-1, the catalytic component of the apoB mRNAediting complex. 44 Studies in the HepG2 hepatoma cell line showed that the length of the ApoB molecule was proportional to nascent lipoprotein core circumference, 45 thus determining lipoprotein sizes and compositions, which may also correlate to different metabolic fates and rates. Therefore, the coexistence of ApoB48 and ApoB100 on VLDL particles secreted from mouse hepatocytes adds a layer of complexity to the interpretation of lipoprotein metabolism. In view of this knowledge, we used human primary hepatocytes to further investigate DGAT1 and DGAT2 functions in VLDL secretion. We found that similar to mouse hepatocytes, DGAT2 in primary human hepatocytes was more important for VLDL maturation than DGAT1 because inhibition of DGAT2 alone significantly diminished triacylglycerol secretion ( Figure 7A ). Moreover, a combination of both DGAT inhibitors nearly abrogated secretion of triacylglycerol synthesized de novo from acetic acid ( Figure 7A ). We could not analyze the secretion of oleic acid-derived triacylglycerol in human hepatocytes on simultaneous inhibition of both DGATs because of a massive cell death under this particular circumstance, likely due to toxic effects of excess free FA. Interestingly, different from mouse hepatocytes, extracellular ApoB100 levels were invariable in acetate-supplemented human hepatocytes even when both DGATs were inhibited ( Figure 7B ). In conclusion, in human hepatocytes, we observed equivalent phenomena as in mouse hepatocytes with respect to contribution of the 2 DGATs to VLDL triacylglycerol secretion: DGAT2 was required for triacylglycerol secretion, on which DGAT1 had a small additive effect. However, extracellular ApoB100 levels remained constant even when both DGATs were inactivated.
Discussion
In this study, we investigated the roles of DGAT1 and DGAT2 in lipid metabolism and VLDL secretion in primary mouse and human hepatocytes by inactivation of DGAT1 and DGAT2 with specific small-molecule inhibitors alone or in combination. We found that in mouse hepatocytes, DGAT1 and DGAT2 can compensate for each other to synthesize triacylglycerol, but the triacylglycerol pool generated by DGAT1 was preferably used for supplying substrates for oxidation, whereas triacylglycerol synthesized by DGAT2 was preferentially used for secretion in VLDL. Inhibition of DGAT2 or both DGATs resulted in accumulation of sn-1,2-diacylglycerol that was diverted to various glycerophospholipid species that also possessed distinct preferences for FA origins. Inhibition of DGAT2 (triacylglycerol synthesized through DGAT1) significantly increased phosphatidylcholine synthesis and slightly decreased triacylglycerol synthesis from exogenous source of oleic acid, and it led to formation of smaller LDs. On the contrary, inactivation of DGAT1 (triacylglycerol synthesized by DGAT2) promoted LD expansion. The differential effects of DGAT1 and DGAT2 on LD morphology in primary mouse hepatocytes are in good agreement with studies in McArdle-RH7777 rat hepatoma cells, where overexpression of Dgat1 led to formation of small LDs around the cell periphery, whereas large LDs were more frequently observed in DGAT2-expressing cells. 5 In addition, similar effects on LD morphology were found in Drosophila melanogaster Schneider 2 cells, where overexpression of Dgat1 or Dgat2 led to large or small LDs, respectively. 26 In all, these results demonstrate a conserved role of DGATs in regulating LD size.
Inhibition of DGAT2 impaired lipogenic gene expression possibly through diminished nuclear presence of transcriptionally active mature SREBP1c. Finally, DGAT2, but not DGAT1, is required for re-esterification of lipolysis-derived diacylglycerol to support VLDL maturation (lipidation). However, extracellular ApoB content did not change in DGAT2-inactivated cells, indicating that similar numbers of lipoprotein particles were secreted, but these particles were less lipidated. Importantly, the dominant role of DGAT2 in VLDL maturation was confirmed in primary human hepatocytes.
Previous studies reported discordant interpretation of results on distinct contributions of DGATs to VLDL maturation, which may stem from the use of different animal and cellular models, dose and time course of virus injection, and other experimental variables. First, some studies showed that adenovirus-mediated Dgat1 overexpression in mice resulted in increased latent DGAT activity and dilated ER, leading to enlarged VLDL with increased triacylglycerol content. 46 This observation is in agreement with studies in McArdle-RH7777 rat hepatoma cells, where overexpression of human Dgat1 increased the secretion of triacylglycerol-enriched VLDL. 47 However, other studies reported that although short-term overexpression of Dgat1 or Dgat2 resulted in increased hepatic triacylglycerol mass, the rate of VLDL production was not affected. 48 Notably, an important role of DGAT1 was reported in the re-esterification of partial glycerides with exogenously derived FA, whereas DGAT2 was proposed to have limited effects on re-esterification. 25, 49 However, these studies used the HepG2 hepatoma cell line, which has been shown to be deficient in the use of preformed triacylglycerol for VLDL assembly, possibly because of the absence of lipases, such as carboxylesterase 1d/triacylglycerol hydrolase and arylacetamide deacetylase. 12, 16, 18, [50] [51] [52] Second, DGAT1-deficient mice fed high-fat diet presented with much lower hepatic triacylglycerol stores but normal plasma triacylglycerol concentration when compared with wild-type control mice, 4 and DGAT1 was found not to be essential for chylomicron formation in mice. 8 On the other hand, DGAT2-deficient mice had low plasma triacylglycerol concentration immediately after birth, 5 which suggests impairment in VLDL secretion; however, a liverspecific Dgat2 −/− mouse model would be required to further test the role of DGAT2 in hepatic triacylglycerol metabolism.
Another important question is the substrate preference of the 2 DGATs. Oleic acid supplementation mimics FA released from adipose tissue or circulating lipoproteins, whereas de novo synthesized FA from acetate represents carbohydrate metabolism. Both sources of FA can be esterified into triacylglycerol for storage or packaged into VLDL particles for secretion. Although previous studies showed preference of DGAT2 for de novo synthesized FA as a substrate for triacylglycerol production, 25, 31 we did not observe any significant differences between DGAT1 and DGAT2 with respect to using endogenously (acetate) or exogenously (oleate) derived FA for triacylglycerol synthesis or secretion.
Interestingly, inhibition of DGAT2 reduced the mature form of SREBP1 in the nucleus, which led to decreased transcription of several lipogenic genes including Acaca, Fasn, Scd1, and Srebf1c itself, whereas inhibition of DGAT1 had no effect on lipogenesis. A role for DGAT2 in the regulation of de novo FA synthesis was reported in HeLa cells where SCD1 was found to physically interact with DGAT2, thereby providing a pool of monounsaturated FAs for triacylglycerol biosynthesis. 53 Because increased Srebf1c expression and FA synthesis in the liver contribute to the development of steatosis in rodent models of insulin resistance and obesity, 1,54 DGAT2 might be an excellent therapeutic target to alleviate lipid metabolic disorders. This potential pharmacological intervention is also supported by studies where attenuation of Dgat2 expression in obese mice by antisense oligonucleotide was shown to improve insulin resistance, steatosis, and hyperlipidemia. 6, 7 Increased FA oxidation was observed after DGAT2 inhibition but not after DGAT1 inhibition. One possible explanation is that FA not targeted for secretion is channeled for oxidation. Another possibility is that DGAT1-generated LDs cannot undergo expansion in the absence of DGAT2, and these smaller LDs are substrates for adipose triglyceride lipase leading to release of FA targeted for oxidation. Figure 8 . A working model of diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 contribution to triacylglycerol (TG) metabolism in hepatocytes. DGAT1 and DGAT2 can compensate for each other to synthesize TG from fatty acid (FA) made de novo (acetate) or exogenously supplied (oleic acid [OA]). A, DGAT1 is a polytopic endoplasmic reticulum (ER) membrane protein. Lipid droplets (LDs) incorporating DGAT1-generated TG are efficiently used for supplying substrates for FA oxidation (FAO) and less capable of expansion. B, DGAT2 intercalates into the ER phospholipid bilayer and cytosolic lipid droplet (CLD) phospholipid monolayer via a long hydrophobic region. TG synthesized by DGAT2 preferentially contributes to very low-density lipoprotein (VLDL) assembly. CLD-associated DGAT2 catalyzes LD expansion. C, DGAT2 is required for VLDL maturation (lipidation) through catalyzing re-esterification of DG originating from lipolysis of pre-existing TG pools. LLD indicates lumenal lipid droplet.
Inhibition of both DGAT1 and DGAT2 activities resulted in extensive cellular death of primary human hepatocytes supplemented with oleic acid followed by prolonged (>12 hours) chase. The cell death could be possibly because of excess free FA that might have accumulated in the ER as a result of not being able to be (re)esterified to triacylglycerol for storage or secretion. Excess free FA elicits profound changes in ER membrane phospholipids, which is followed by ER deformation and leakage of protein-folding chaperones to the cytosol. 55, 56 In addition, alterations in mitochondrial membrane phospholipids and activation of nicotinamide adenine dinucleotide phosphate oxidase by diacylglycerol through protein kinase C-dependent pathways produce reactive oxygen species, release cytochrome c, and result in mitochondrial dysfunction. 56, 57 Currently, it is not clear how the cytosolic topology of DGAT2 active site contributes to VLDL assembly. ER-localized DGAT2 should only contribute to the overt DGAT activity. However, pharmacological inhibition of DGAT2 by niacin decreased both overt and latent DGAT activities by 30%. 58 Therefore, integration of DGAT1 and DGAT2 function with their topologies requires further experimentation. A working model of DGAT1 and DGAT2 contribution to lipid metabolism in hepatocytes is presented in Figure 8 . DGAT1 and DGAT2 can compensate for each other to synthesize triacylglycerol in hepatocytes, but the triacylglycerol pool synthesized by DGAT1 and stored in small LDs is more effectively used for supplying substrates for oxidation, whereas DGAT2 generates triacylglycerol for storage in large LDs and VLDL lipidation via re-esterification of diacylglycerol derived from lipolysis of preformed triacylglycerol stores.
